These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32634290)

  • 1. Recoding the Cancer Epigenome by Intervening in Metabolism and Iron Homeostasis with Mitochondria-Targeted Rhenium(I) Complexes.
    Pan ZY; Tan CP; Rao LS; Zhang H; Zheng Y; Hao L; Ji LN; Mao ZW
    Angew Chem Int Ed Engl; 2020 Oct; 59(42):18755-18762. PubMed ID: 32634290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted reversal and phosphorescence lifetime imaging of cancer cell metabolism via a theranostic rhenium(I)-DCA conjugate.
    Yang J; Cao Q; Zhang H; Hao L; Zhou D; Gan Z; Li Z; Tong YX; Ji LN; Mao ZW
    Biomaterials; 2018 Sep; 176():94-105. PubMed ID: 29870900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mono- and Dinuclear Phosphorescent Rhenium(I) Complexes: Impact of Subcellular Localization on Anticancer Mechanisms.
    Ye RR; Tan CP; Chen MH; Hao L; Ji LN; Mao ZW
    Chemistry; 2016 Jun; 22(23):7800-9. PubMed ID: 27106876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondria-targeted Re(I) complexes bearing guanidinium as ligands and their anticancer activity.
    He SF; Pan NL; Chen BB; Liao JX; Huang MY; Qiu HJ; Jiang DC; Wang JJ; Chen JX; Sun J
    J Biol Inorg Chem; 2020 Dec; 25(8):1107-1116. PubMed ID: 33079244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondria-Accumulating Rhenium(I) Tricarbonyl Complexes Induce Cell Death via Irreversible Oxidative Stress and Glutathione Metabolism Disturbance.
    Wang FX; Liang JH; Zhang H; Wang ZH; Wan Q; Tan CP; Ji LN; Mao ZW
    ACS Appl Mater Interfaces; 2019 Apr; 11(14):13123-13133. PubMed ID: 30888144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phosphorescent rhenium(I) histone deacetylase inhibitor: mitochondrial targeting and paraptosis induction.
    Ye RR; Tan CP; Lin YN; Ji LN; Mao ZW
    Chem Commun (Camb); 2015 May; 51(39):8353-6. PubMed ID: 25882790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Anticancer Activity and in Vivo Biodistribution of Rhenium(I) Tricarbonyl Aqua Complexes.
    Knopf KM; Murphy BL; MacMillan SN; Baskin JM; Barr MP; Boros E; Wilson JJ
    J Am Chem Soc; 2017 Oct; 139(40):14302-14314. PubMed ID: 28948792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy.
    Sandoval-Acuña C; Torrealba N; Tomkova V; Jadhav SB; Blazkova K; Merta L; Lettlova S; Adamcová MK; Rosel D; Brábek J; Neuzil J; Stursa J; Werner L; Truksa J
    Cancer Res; 2021 May; 81(9):2289-2303. PubMed ID: 33685989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
    Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
    BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dinuclear Rhenium(I) Tricarbonyl Complexes as Anticancer Drug Candidates.
    Montesdeoca N; Borkar RL; Sathiyendiran M; Karges J
    Chemistry; 2024 Jun; 30(32):e202400217. PubMed ID: 38574234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
    Calabrese C; Panuzzo C; Stanga S; Andreani G; Ravera S; Maglione A; Pironi L; Petiti J; Shahzad Ali MS; Scaravaglio P; Napoli F; Fava C; De Gobbi M; Frassoni F; Saglio G; Bracco E; Pergolizzi B; Cilloni D
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Study of Sonodynamic and Photoactivated Cancer Therapies with Re(I)-Tricarbonyl Complexes Comprising Phenanthroline Ligands.
    Kushwaha R; Singh V; Peters S; Yadav AK; Sadhukhan T; Koch B; Banerjee S
    J Med Chem; 2024 Apr; 67(8):6537-6548. PubMed ID: 38603561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.
    Tataranni T; Mazzoccoli C; Agriesti F; De Luca L; Laurenzana I; Simeon V; Ruggieri V; Pacelli C; Della Sala G; Musto P; Capitanio N; Piccoli C
    Stem Cell Res Ther; 2019 Jun; 10(1):171. PubMed ID: 31196186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.
    Tataranni T; Agriesti F; Mazzoccoli C; Ruggieri V; Scrima R; Laurenzana I; D'Auria F; Falzetti F; Di Ianni M; Musto P; Capitanio N; Piccoli C
    Br J Haematol; 2015 Jul; 170(2):236-46. PubMed ID: 25825160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorescent rhenium(I) complexes conjugated with artesunate: Mitochondrial targeting and apoptosis-ferroptosis dual induction.
    Ye RR; Chen BC; Lu JJ; Ma XR; Li RT
    J Inorg Biochem; 2021 Oct; 223():111537. PubMed ID: 34273716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
    Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
    Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment:
    Abdel-Wahab ND; Kabil MF; El-Sherbiny IM; Salama MF; El-Sayed G; El-Sherbini ES
    Drug Dev Ind Pharm; 2024 Mar; 50(3):223-235. PubMed ID: 38305197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells.
    González-Bártulos M; Aceves-Luquero C; Qualai J; Cussó O; Martínez MA; Fernández de Mattos S; Menéndez JA; Villalonga P; Costas M; Ribas X; Massaguer A
    PLoS One; 2015; 10(9):e0137800. PubMed ID: 26368127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhenium N-heterocyclic carbene complexes block growth of aggressive cancers by inhibiting FGFR- and SRC-mediated signalling.
    Domenichini A; Casari I; Simpson PV; Desai NM; Chen L; Dustin C; Edmands JS; van der Vliet A; Mohammadi M; Massi M; Falasca M
    J Exp Clin Cancer Res; 2020 Dec; 39(1):276. PubMed ID: 33287862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
    Tury S; Assayag F; Bonin F; Chateau-Joubert S; Servely JL; Vacher S; Becette V; Caly M; Rapinat A; Gentien D; de la Grange P; Schnitzler A; Lallemand F; Marangoni E; Bièche I; Callens C
    J Pathol; 2018 Sep; 246(1):103-114. PubMed ID: 29876931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.